ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2016
TGF-β receptor 1 inhibition prevents stenosis of tissue-engineered vascular grafts by reducing host mononuclear phagocyte activation.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Tissue-engineered Vascular Grafts in Children With Congenital Heart Disease: Intermediate Term Follow-up.Seminars in thoracic and cardiovascular surgery · 2018Trial
- Rolled amniotic membrane for practical vascular graft development: a scoping review.Human cell · 2026Article
- Modulating the platelet-mediated innate foreign body response to affect in situ vascular tissue engineering outcomes.NPJ Regenerative medicine · 2025Article
- Harnessing the potential of monocytes/macrophages to regenerate tissue-engineered vascular grafts.Cardiovascular research · 2024Review
- Tissue Engineering of Vascular Grafts: A Case Report From Bench to Bedside and Back.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- Immunomodulation Strategies for the Successful Regeneration of a Tissue-Engineered Vascular Graft.Advanced healthcare materials · 2022Review
- Strategies to counteract adverse remodeling of vascular graft: A 3D view of current graft innovations.Frontiers in bioengineering and biotechnology · 2022Review
- Complications and management of functional single ventricle patients with Fontan circulation: From surgeon's point of view.Frontiers in cardiovascular medicine · 2022Review
- A computational bio-chemo-mechanical model of in vivo tissue-engineered vascular graft development.Integrative biology : quantitative biosciences from nano to macro · 2020Article
- Spontaneous reversal of stenosis in tissue-engineered vascular grafts.Science translational medicine · 2020Article
- Imatinib attenuates neotissue formation during vascular remodeling in an arterial bioresorbable vascular graft.JVS-vascular science · 2020Article
- Degradation andRegenerative medicine · 2019Article
- Early natural history of neotissue formation in tissue-engineered vascular grafts in a murine model.Regenerative medicine · 2019Article
- Immuno-driven and Mechano-mediated Neotissue Formation in Tissue Engineered Vascular Grafts.Annals of biomedical engineering · 2018Article
- Bone marrow-derived mononuclear cell seeded bioresorbable vascular graft improves acute graft patency by inhibiting thrombus formation via platelet adhesion.International journal of cardiology · 2018Article
- Quickening: Translational design of resorbable synthetic vascular grafts.Biomaterials · 2018Review
- Angiotensin II receptor I blockade prevents stenosis of tissue engineered vascular grafts.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018Article
- Mapping macrophage polarization over the myocardial infarction time continuum.Basic research in cardiology · 2018Article
- Future Perspectives on the Role of Stem Cells and Extracellular Vesicles in Vascular Tissue Regeneration.Frontiers in cardiovascular medicine · 2018Review
- Tissue-engineered vascular grafts for congenital cardiac disease: Clinical experience and current status.Trends in cardiovascular medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Stenosis is a critical problem in the long-term efficacy of tissue-engineered vascular grafts (TEVGs). We previously showed that host monocyte infiltration and activation within the graft drives stenosis and that TGF-β receptor 1 (TGF-βR1) inhibition can prevent it, but the latter effect was attributed primarily to inhibition of mesenchymal cell expansion. In this study, we assessed the effects of TGF-βR1 inhibition on the host monocytes. Biodegradable TEVGs were implanted as inferior vena cava interposition conduits in 2 groups of C57BL/6 mice (n = 25/group): unseeded grafts and unseeded grafts with TGF-βR1 inhibitor systemic treatment for the first 2 wk. The TGF-βR1 inhibitor treatment effectively improved TEVG patency at 6 mo compared to the untreated control group (91.7 vs. 48%, P < 0.001), which is associated with a reduction in classic activation of mononuclear phagocytes. Consistent with these findings, the addition of rTGF-β to LPS/IFN-γ-stimulated monocytes enhanced secretion of inflammatory cytokines TNF-α, IL-12, and IL-6; this effect was blocked by TGF-βR1 inhibition (P < 0.0001). These findings suggest that the TGF-β signaling pathway contributes to TEVG stenosis by inducing classic activation of host monocytes. Furthermore, blocking monocyte activation by TGF-βR1 inhibition provides a viable strategy for preventing TEVG stenosis while maintaining neotissue formation.-Lee, Y.-U., de Dios Ruiz-Rosado, J., Mahler, N., Best, C. A., Tara, S., Yi, T., Shoji, T., Sugiura, T., Lee, A. Y., Robledo-Avila, F., Hibino, N., Pober, J. S., Shinoka, T., Partida-Sanchez, S., Breuer, C. K. TGF-β receptor 1 inhibition prevents stenosis of tissue-engineered vascular grafts by reducing host mononuclear phagocyte activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.